Sergei P Atamas1, Barbara White. 1. Baltimore Veterans Administration Medical Center, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA. satamas@umaryland.edu
Abstract
PURPOSE OF REVIEW: The triad of pathologic changes that defines systemic sclerosis (scleroderma) includes immune system activation with autoimmunity; an obliterative, proliferative small vessel vasculopathy; and fibrosis. Available data suggest that several cytokines, including chemokines, contribute to the development of scleroderma complications. This review focuses on chemokines and their contribution to tissue fibrosis and pulmonary hypertension in scleroderma. RECENT FINDINGS: Proteins and mRNAs for monocyte chemoattractant protein-1; pulmonary and activation-regulated chemokine; macrophage inflammatory protein-1, regulated upon activation normal T cell expressed and secreted; interleukin-8; and transforming growth factor-beta have been found in increased amounts in blood or involved tissue from scleroderma patients. These factors are likely to contribute directly to tissue damage in scleroderma through several pathways, including stimulation of extracellular matrix production, induction of TGF-beta production and activation, and chemoattraction of T cells and nonspecific inflammatory cells into tissues. SUMMARY: Multiple chemokines are part of the pathologic network that causes tissue damage in scleroderma, and, as such, may provide therapeutic targets in scleroderma.
PURPOSE OF REVIEW: The triad of pathologic changes that defines systemic sclerosis (scleroderma) includes immune system activation with autoimmunity; an obliterative, proliferative small vessel vasculopathy; and fibrosis. Available data suggest that several cytokines, including chemokines, contribute to the development of scleroderma complications. This review focuses on chemokines and their contribution to tissue fibrosis and pulmonary hypertension in scleroderma. RECENT FINDINGS: Proteins and mRNAs for monocyte chemoattractant protein-1; pulmonary and activation-regulated chemokine; macrophage inflammatory protein-1, regulated upon activation normal T cell expressed and secreted; interleukin-8; and transforming growth factor-beta have been found in increased amounts in blood or involved tissue from sclerodermapatients. These factors are likely to contribute directly to tissue damage in scleroderma through several pathways, including stimulation of extracellular matrix production, induction of TGF-beta production and activation, and chemoattraction of T cells and nonspecific inflammatory cells into tissues. SUMMARY: Multiple chemokines are part of the pathologic network that causes tissue damage in scleroderma, and, as such, may provide therapeutic targets in scleroderma.
Authors: William E O'Gorman; Elena W Y Hsieh; Erica S Savig; Pier Federico Gherardini; Joseph D Hernandez; Leo Hansmann; Imelda M Balboni; Paul J Utz; Sean C Bendall; Wendy J Fantl; David B Lewis; Garry P Nolan; Mark M Davis Journal: J Allergy Clin Immunol Date: 2015-05-30 Impact factor: 10.793
Authors: S P Atamas; I G Luzina; J Ingels; J Choi; W K Wong; D E Furst; P J Clements; A E Postlethwaite Journal: Clin Exp Immunol Date: 2010-09 Impact factor: 4.330
Authors: T Bohgaki; Y Amasaki; N Nishimura; M Bohgaki; Y Yamashita; M Nishio; K-I Sawada; S Jodo; T Atsumi; T Koike Journal: Ann Rheum Dis Date: 2005-08 Impact factor: 19.103
Authors: Irina G Luzina; Pavel Kopach; Virginia Lockatell; Phillip H Kang; Ashish Nagarsekar; Allen P Burke; Jeffrey D Hasday; Nevins W Todd; Sergei P Atamas Journal: Am J Respir Cell Mol Biol Date: 2013-12 Impact factor: 6.914
Authors: Dmitry N Grigoryev; Stephen C Mathai; Micah R Fisher; Reda E Girgis; Ari L Zaiman; Traci Housten-Harris; Christopher Cheadle; Li Gao; Laura K Hummers; Hunter C Champion; Joe G N Garcia; Fredrick M Wigley; Rubin M Tuder; Kathleen C Barnes; Paul M Hassoun Journal: Transl Res Date: 2008-02-01 Impact factor: 7.012
Authors: Paola Coral-Alvarado; Gerardo Quintana; Maria Fernanda Garces; Libia Alexandra Cepeda; Jorge Eduardo Caminos; Federico Rondon; Antonio Iglesias-Gamarra; Jose Felix Restrepo Journal: Rheumatol Int Date: 2008-12-31 Impact factor: 2.631